Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced positive topline results from its INTEGUMENT-1 Phase 3 trial for roflumilast cream 0.15% in treating mild to moderate atopic dermatitis. The primary endpoint was met, with 32.0% achieving IGA Success compared to 15.2% for the vehicle (P<0.0001). Key results include 43.2% achieving EASI-75 and 33.6% reporting reduced itch by Week 4. Roflumilast cream demonstrated a favorable safety profile, with minimal adverse events. Topline results from the INTEGUMENT-2 trial are expected by year-end.
Arcutis Biotherapeutics announced positive results from the INTEGUMENT-1 pivotal Phase 3 trial of its roflumilast cream 0.15%, targeting mild to moderate atopic dermatitis in patients aged six years and older. The treatment met its primary endpoint, with 32.0% of participants achieving Investigator Global Assessment (IGA) Success compared to 15.2% with vehicle (P0.0001). Secondary endpoints showed 43.2% achieved EASI-75, and 33.6% reported meaningful itch reduction by Week 4. Roflumilast cream exhibited a favorable safety profile, with low adverse event rates. Results from the INTEGUMENT-2 trial are expected by year-end.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced its participation in the Guggenheim 4th Annual Immunology and Neurology Day investor conference. The fireside chat is scheduled for November 15, 2022, at 10:45 a.m. ET. Investors can access the webcast through the Company’s website.
Arcutis focuses on addressing needs in immuno-dermatology through innovative therapies targeting conditions like psoriasis and dermatitis.
Arcutis Biotherapeutics reported third-quarter results with net revenues of $0.7 million from the launch of ZORYVE for plaque psoriasis in August 2022. The company achieved coverage for ZORYVE from a leading pharmacy benefit manager and a national health plan. It completed the enrollment for two pivotal Phase 3 trials for atopic dermatitis, with topline data expected by year-end. Additionally, Arcutis acquired Ducentis BioTherapeutics, enhancing its pipeline. As of September 30, 2022, the company holds approximately $480 million in cash and equivalents.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced a conference call and webcast on November 8, 2022, at 5:00 p.m. ET to discuss its Q3 2022 financial results. The press release will be available after U.S. market close on the same day. Arcutis specializes in developing innovative therapies for immune-mediated dermatological diseases, utilizing a robust development platform with multiple clinical programs targeting conditions like scalp psoriasis and atopic dermatitis. For more details, visit www.arcutis.com.
Summary not available.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the grant of 32,300 restricted stock units and options for 85,800 shares to nine new employees, as approved by its Compensation Committee. These awards were made under the 2022 Inducement Plan, with the grant date set on September 1, 2022. The restricted stock units vest over four years, while the stock options have a ten-year term and an exercise price of $19.20 per share, equal to the closing price on October 3, 2022. This initiative aims to attract key talent as part of Arcutis’ ongoing growth in immuno-dermatology.
Arcutis Biotherapeutics announced positive results from the Phase 3 ARRECTOR trial of roflumilast foam 0.3% for scalp and body psoriasis. The study met both co-primary endpoints: 67.3% of participants achieved S-IGA Success versus 28.1% with a vehicle, while 46.5% achieved B-IGA Success compared to 20.8%. Roflumilast foam demonstrated a favorable safety profile, with a majority completing the trial. Arcutis plans to file a New Drug Application based on these results, highlighting the foam's potential to address unmet needs in psoriasis treatment.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced positive results from two pivotal Phase 3 studies published in JAMA, evaluating its roflumilast cream for chronic plaque psoriasis treatment. In these studies, 40% of treated patients achieved Investigator Global Assessment success at eight weeks, significantly outperforming the vehicle group. Key findings include around 70% achieving intertriginous-IGA success and approximately 40% reaching PASI-75. Roflumilast showed rapid improvements in itch and plaque clearance, with a favorable safety profile.
Arcutis Biotherapeutics has announced positive data from the STRATUM Phase 3 trial of its investigational roflumilast foam for treating seborrheic dermatitis in adults and children 9 and older. The study achieved its primary endpoint, with 80.1% of patients achieving 'IGA Success' compared to 59.2% with vehicle (P<0.0001). Over 60% experienced significant itch relief by week 8. All secondary endpoints also showed statistically significant improvements. Roflumilast foam was well-tolerated, showing no serious adverse events, and an NDA submission is planned for Q1 2023.